

AMENDMENTS TO THE CLAIMS

1. (Currently amended) The method of claim 35, wherein the [[A]] recombinant herpes simplex virus (HSV) particle further comprises at least a second ~~having at least one protein on its surface, comprising: (a) an altered viral surface protein, wherein the alteration reduces binding of the second viral surface protein to a sulfated proteoglycan; (b) an altered gD, wherein the alteration reduces binding of gD to one or more of its cellular receptors; and (c) a heterologous peptide ligand on the surface of the recombinant HSV particle, the heterologous peptide ligand forming a fusion protein with the altered gD, whereby the HSV particle exhibits specific affinity for a cell surface component that is not a natural viral receptor.~~

2. (Currently amended) The method of recombinant HSV particle of claim 1, wherein the second altered viral surface protein is selected from the group consisting of gB and gC.

3. (Canceled)

4. (Currently amended) The method of claim 35 recombinant HSV particle of claim 1, wherein the altered gD exhibits reduced ~~alteration of gD~~ reduces binding to HveA or HveC.

5. (Canceled)

6. (Currently amended) The method of claim 35 recombinant HSV particle of claim 1, wherein the recombinant HSV comprises a second fusion protein comprising a ligand fused with ~~forms a second fusion protein with~~ a viral surface protein selected from the group consisting of gB and gC.

7. (Canceled)

8. (Currently amended) The method of claim 35 recombinant HSV particle of claim 1, wherein the ligand binds a receptor on the surface of a cell.

9. (Currently amended) The method of claim 35 recombinant HSV particle of claim 8, wherein the target cell is a cancer cell.

10. (Currently amended) The method ~~recombinant HSV particle~~ of claim 9, wherein the cancer cell is a tumor cell.

11. (Currently amended) The method ~~recombinant HSV particle~~ of claim 9, wherein the cancer cell is a malignant gliomal cell.

12. (Currently amended) The method of claim 35 ~~recombinant HSV particle of claim 1~~, wherein the ligand is a cytokine.

13. (Currently amended) The method ~~recombinant HSV particle~~ of claim 12, wherein the cytokine is IL13.

14. (Currently amended) The method of claim 35, wherein ~~recombinant HSV particle of claim 1~~, the ligand is a single-chain antibody.

15-21. (Canceled)

22. (Currently amended) The method of claim ~~6~~ 15, wherein the second fusion protein comprises a ligand fused ~~forms a fusion protein~~ with gC.

23-34. (Canceled)

35. (Currently amended) A method of killing a target cell, comprising contacting the target cell with a recombinant HSV particle, wherein the HSV particle comprises an altered gD forming a fusion with a peptide ligand to a receptor specific to the cell wherein the altered gD exhibits reduced binding to at least one of the cellular receptors of wild type gD.

36.-49. (Canceled)